ENSC vs NKTR vs HALO vs COLL

For growth investors, Ensysce Biosciences, Inc.

(ENSC) is the stronger pick with 133. 5% revenue growth year-over-year, versus -43. 9% for Nektar Therapeutics (NKTR). Collegium Pharmaceutical, Inc. (COLL) offers the better valuation at 21. 8x trailing P/E (5. 1x forward), making it the more compelling value choice. Analysts rate Nektar Therapeutics (NKTR) a "Buy" — based on 33 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Collegium Pharmaceutical, Inc.

(COLL) is the cheapest at 21. 8x versus Halozyme Therapeutics, Inc. at 25. 0x. On forward P/E, Collegium Pharmaceutical, Inc. is actually cheaper at 5. 1x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Collegium Pharmaceutical, Inc. wins at 0. 28x versus Halozyme Therapeutics, Inc. 's 0. 35x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Collegium Pharmaceutical, Inc.

(COLL) delivered a total return of +71. 9%, compared to -100. 0% for Ensysce Biosciences, Inc. (ENSC). Over 10 years, the gap is even starker: HALO returned +559. 7% versus ENSC's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Halozyme Therapeutics, Inc.

(HALO) is the lower-risk stock at 0. 51β versus Nektar Therapeutics's 1. 80β — meaning NKTR is approximately 251% more volatile than HALO relative to the S&P 500. On balance sheet safety, Ensysce Biosciences, Inc. (ENSC) carries a lower debt/equity ratio of 9% versus 3% for Collegium Pharmaceutical, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Ensysce Biosciences, Inc.

(ENSC) is pulling ahead at 133. 5% versus -43. 9% for Nektar Therapeutics (NKTR). On earnings-per-share growth, the picture is similar: Ensysce Biosciences, Inc. grew EPS 2. 6% year-over-year, compared to -25. 4% for Halozyme Therapeutics, Inc.. Over a 3-year CAGR, HALO leads at 28. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Halozyme Therapeutics, Inc.

(HALO) is the more profitable company, earning 22. 7% net margin versus -297. 1% for Nektar Therapeutics — meaning it keeps 22. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HALO leads at 58. 4% versus -236. 8% for NKTR. At the gross margin level — before operating expenses — NKTR leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Collegium Pharmaceutical, Inc. (COLL) is the more undervalued stock at a PEG of 0. 28x versus Halozyme Therapeutics, Inc. 's 0. 35x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Collegium Pharmaceutical, Inc. (COLL) trades at 5. 1x forward P/E versus 8. 0x for Halozyme Therapeutics, Inc. — 2. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NKTR: 79. 9% to $147. 33.

In this comparison, ENSC (100.

0% yield) pays a dividend. NKTR, HALO, COLL do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Halozyme Therapeutics, Inc.

(HALO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 51), +559. 7% 10Y return). Nektar Therapeutics (NKTR) carries a higher beta of 1. 80 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (HALO: +559. 7%, NKTR: -59. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ENSC is a small-cap high-growth stock; NKTR is a small-cap quality compounder stock; HALO is a small-cap high-growth stock; COLL is a small-cap high-growth stock. ENSC pays a dividend while NKTR, HALO, COLL do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.